Single User
£3698
PDF
42 pages

Prostate Cancer Forecast in 18 Major Markets 2016-2026


Prostate cancer is one of the most common cancers in men. The prostate, found only in men, is the size and shape of a walnut and grows bigger with age. It sits underneath the bladder and in front of the rectum. It surrounds part of the urethra which is a tube that carries urine from the bladder. A key function of the prostate is the production of semen. Prostate Cancer is predominantly a disease of older men but around 20-30% of cases occur in men under the age of 65 years of age.

This report provides the current incident population for Prostate Cancer across 18 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, Argentina, Australia, Canada, India, Mexico, Russian Federation, Saudi Arabia, South Africa, Turkey and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Prostate Cancer have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Symptoms of prostate cancer can be similar to those of patients with benign prostatic hyperplasia (BPH), but can include lower urinary tract symptoms such as:

  • Needing to urinate more frequently, often during the night (nocturia)
  • Needing to rush to the toilet (urgency)
  • Difficulty in starting to urinate (hesitancy)
  • Straining or taking a long time while urinating
  • Weak flow
  • Feeling that the bladder has not emptied fully

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
  • Able to quantify patient populations in global Prostate Cancer’s market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the incidence of the subdivided types of Prostate Cancer and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Prostate Cancer’s incident population.
  • Identify sub-populations within Prostate Cancer which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Prostate Cancer patients.
Table of Contents
  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key Co-morbid Conditions/Features Associated with the Disease
  • Methodology for Quantification of Patient Numbers
  • Top-Line Incidence for Prostate Cancer
  • Features of Prostate Cancer Patients
    • Prostate Cancer by Stage
    • Treated Prostate Cancer Patients by Hormonal Status
  • Abbreviations used in the Report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix
List of Figures
  • Diagrammatic Image of the Prostate
List of Tables
  • The Gleason Grading System
  • Incidence of Prostate Cancer, males (000s)
  • Treatment Eligible Prostate Cancer Patients, males (000s)
  • Prostate Cancer patients by stage, males (000s)
  • Treated Prostate Cancer patients by Hormonal Status, males (000s)
  • Treated Castrate-Resistant Metastatic Prostate Cancer patients, males (000s)
  • BRCA 1 mutation in Prostate Cancer patients, males (000s)
  • BRCA 2 mutation in Prostate Cancer patients, males (000s)
  • Cachexia in Prostate Cancer patients, males (000s)
  • Abbreviations and Acronyms used in the report
  • USA Incidence of Prostate Cancer by 5-yr age cohort, males (000s)
  • France Incidence of Prostate Cancer by 5-yr age cohort, males (000s)
  • Germany Incidence of Prostate Cancer by 5-yr age cohort, males (000s)
  • Italy Incidence of Prostate Cancer by 5-yr age cohort, males (000s)
  • Spain Incidence of Prostate Cancer by 5-yr age cohort, males (000s)
  • UK Incidence of Prostate Cancer by 5-yr age cohort, males (000s)
  • Brazil Incidence of Prostate Cancer by 5-yr age cohort, males (000s)
  • Japan Incidence of Prostate Cancer by 5-yr age cohort, males (000s)
  • Argentina Incidence of Prostate Cancer by 5-yr age cohort, males (000s)
  • Australia Incidence of Prostate Cancer by 5-yr age cohort, males (000s)
  • Canada Incidence of Prostate Cancer by 5-yr age cohort, males (000s)
  • India Incidence of Prostate Cancer by 5-yr age cohort, males (000s)
  • Mexico Incidence of Prostate Cancer by 5-yr age cohort, males (000s)
  • Russian Federation Incidence of Prostate Cancer by 5-yr age cohort, males (000s)
  • Saudi Arabia Incidence of Prostate Cancer by 5-yr age cohort, males (000s)
  • South Africa Incidence of Prostate Cancer by 5-yr age cohort, males (000s)
  • Turkey Incidence of Prostate Cancer by 5-yr age cohort, males (000s)
  • China Incidence of Prostate Cancer by 5-yr age cohort, males (000s)
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Russian Federation, Saudi Arabia, South Africa, Spain, Turkey, United Kingdom, United States of America